News

Promega and SignalChem Pharma said that the solution is a combination of an expanding series of Kinase Enzyme Systems and Promega’s new, bioluminescent ADP-Glo Kinase Assay, which is

According to the agreement, Swedish Orphan Biovitrum will be dealing with the marketing and sales of Dongbao’s pipeline of biopharmaceuticals and other drugs in Europe. Whereas, Dongbao will

Ablynx said that IWT grant will help the company to accelerate ALX-0171 pre-clinical development programme for the treatment of respiratory syncytial virus (RSV) infections. In the trial, ALX-0171

Erwinase is an L-asparaginase derived from Erwinia chrysanthemi, used for the treatment of acute lymphoblastic leukemia in combination with other anti-neoplastic agents. Erwinase is currently approved for use

Takeda Pharma said that Rozerem is for the treatment of insomnia. It works by selectively targeting two melatonin receptors in the brain, MT1 and MT2. Earlier, in July

DX-88 (ecallantide) has been approved by the FDA and is marketed as Kalbitor (ecallantide) for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years

Biomagnetics plans to release the technology, initially targeting cholera and tuberculosis, into the public sector upon completion of the prior work. Under the agreement, the scientific and engineering

MOR202 is a fully human, HuCAL antibody directed against CD38, a membrane- bound glycoprotein that is a potential therapeutic target for the treatment of multiple myeloma and certain

Pharming said it was into an ongoing manufacturing agreement with MSD (formerly Schering-Plough/Organon) for the production of Ruconest, since 2005. Pharming is expected to launch and supply the